RealTime Dynamix™: Rheumatoid Arthritis US Q1
The US biologics and small molecule market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades, more recent launches, an active pipeline, and the imminent introduction of biosimilars present an […]
RealTime Dynamix™: Crohn’s Disease Q1
Crohn’s Disease (CD) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. Theintroduction of biologics has changed the face of treatment for moderateto-severe CD patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the CD landscape. […]
RealTime Dynamix™: Ulcerative Colitis Q1
Ulcerative Colitis (UC) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. The introduction of biologics has changed the face of treatment for moderateto-severe UC patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the UC […]
RealTime Dynamix™: Multiple Sclerosis Q1
The Multiple Sclerosis (MS) market is more dynamic and complex than ever with several disease-modifying therapies (DMTs) currently available and a potential game-changer entry, in the form of Roche/Genentech’s Ocrevus (ocrelizumab), approved by the FDA on March 28, 2017. RealTime Dynamix™: Multiple Sclerosis allows marketing professionals to keep abreast and react to these market changes […]
RealTime Dynamix™: Hyperkalemia (Neph) Q1
The hyperkalemia market underwent sweeping changes with the introduction of Relypsa’s Veltassa in the beginning of 2016. Veltassa represented the first new therapy for the treatment of hyperkalemia in over 50 years. In 2017, a new competitor in AstraZeneca/ZS Pharma’s ZS-9 may come into play after being delayed by a Complete Response Letter in 2016. […]
Will US Rheumatologists Follow in the Footsteps of Dermatologists for Adoption of Eli Lilly’s Taltz?
CAMBRIDGE, Mass., Jan. 26, 2017 /PRNewswire/ — A recent study of 100 surveyed US rheumatologists, reveals that after viewing a product profile for the likely second to market IL-17 inhibitor for PsA, 84% anticipate prescribing Lilly’s Taltz (ixekizumab), if approved. Furthermore, the vast majority of rheumatologists plan to initiate treatment within the first-year of launch. […]
Extended FDA Review for Lilly/Incyte’s Olumiant (baricitinib) in Rheumatoid Arthritis Delays Market Entry for First Major Competitor to Pfizer’s Xeljanz
And Sanofi-Regeneron’s IL-6 inhibitor, sarilumab, also getting back on track after receiving a Complete Response Letter from the FDA in October 2016. The competition to be the preferred first-line, non-TNF agent in the treatment RA is expected to be fierce in 2017, according to a new report from Spherix Global Insights Cambridge, Massachusetts. (PRWEB) January […]
Studies of the Multiple Sclerosis (MS) Market Highlight the Increasing Penetration of Oral Disease-modifying Therapies (DMTs) into First Line Position
ZUG, Switzerland, Jan. 17, 2017 /PRNewswire/ — The MS market has shifted over the course of 2016 according to the Q4 update of RealTime Dynamix™, an independent report based on survey responses of 100 US neurologists who actively manage patients with MS. According to the study, oral DMTs captured a significantly higher share at the […]
Eli Lilly’s Taltz Gaining Ground in Psoriasis Market, Leaving Novartis’ Cosentyx at Risk in 2017, according to Spherix Global Insights
Though Cosentyx significantly leads the PsO market in biologic patient share and satisfaction; over 100 surveyed US dermatologists’ projected share at six months out reveals the two IL-17 inhibitors as neck and neck. Download Report Overview CAMBRIDGE, Mass., Nov. 29, 2016 /PRNewswire/ — At just over six months post launch, US dermatologists report a significant […]
RealTime Dynamix™: Psoriasis
RealTime Dynamix: Psoriasis Q2 is the baseline first report in a three-part 2016 series focusing on current and anticipated future trends in the PsO market. Report content includes current and future patient share, treatment satisfaction, industry contact rates, awareness and familiarity with products in development, sources of information about development compounds, statement agreements, line of […]
